745013-59-6
745013-59-6 structure
- Name: Tremelimumab
- Chemical Name: Tremelimumab
- CAS Number: 745013-59-6
- Molecular Formula:
- Molecular Weight:
- Catalog: Research Areas Cancer
- Create Date: 2019-02-17 05:46:46
- Modify Date: 2024-01-05 21:36:39
-
Tremelimumab (Ticilimumab) is a fully humanized monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research[1].
| Name | Tremelimumab |
|---|---|
| Synonyms |
Ticilimumab
CP-675206 |
| Description | Tremelimumab (Ticilimumab) is a fully humanized monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Tremelimumab (Ticilimumab) has a higher affinity for CTLA-4-Ig than for CD28-Ig and that the antibody is specific for cynomolgus monkeys and humans[1]. Tremelimumab does not bind to human leukocyte FcγR and does not trigger the release of cytokines avoiding the cytokine release syndrome, but increases the IL-2 production upon stimulation with the staphylococcal enterotoxin A in a concentration-dependent manner[1]. Tremelimumab enhances the IL-2 production in T-cells[1]. |
| References |
| Storage condition | 2-8°C |
|---|